• Users Online: 1787
  • Print this page
  • Email this page
REVIEW ARTICLE
Year : 2016  |  Volume : 7  |  Issue : 1  |  Page : 6-11

Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients


1 Department of Dermatology, Dr. D. Y. Patil Medical College and Hospital, Mumbai, Maharashtra, India
2 Department of Dermatology, Apollo Hospitals, Chennai, Tamil Nadu, India
3 Department of Dermatology, Max Super Speciality Hospital, New Delhi, India
4 Department of Dermatology, Batra Hospital, New Delhi, India
5 Department of Dermatology, B. J. Medical College and Civil Hospital, Ahmedabad, Gujarat, India
6 Department of Research, Institute of Pulmonology, Medical Research and Development, Mumbai, Maharashtra, India
7 Dr. Sushil Tahiliani Clinic, Mumbai, Maharashtra, India
8 Dr. Krupa Shankar Skin Diagnosis Center, Mallige Medical Centre Pvt. Ltd., Bengaluru, Karnataka, India
9 Somani Skin Care Centre, Hyderabad, Telangana, India
10 Skin Diseases Center, Nashik, Maharashtra, India

Correspondence Address:
Dr. Kiran Godse
Department of Dermatology, Dr. D. Y. Patil Medical College and Hospital, Nerul, Mumbai - 400 706, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2229-5178.174314

Rights and Permissions

Chronic spontaneous urticaria (CSU) affects 1% of the world population and also their quality of life, and 50% of these patients are refractory to H1-antihistamines. Omalizumab is a humanized monoclonal anti-IgE antibody that binds with free IgE antibodies and reduces the circulating levels of free IgE. This reduction in free IgE prevents mast-cell degranulation. The EAACI/GA2LEN/EDF/WAO guidelines recommend omalizumab as the third-line of therapy as an add-on to antihistamines. The recommended dose of omalizumab is 300 mg, 4 weekly in the management of CSU refractory to standard of care with H1-antihistamines in adults and adolescents ≥12 years of age. In some patients, a dose of 150 mg may be acceptable. Omalizumab has a good safety profile. However, due to the biologic nature of the drug, all patients administered omalizumab must be observed for 2 h after administration for anaphylactoid reactions. There have been no studies on the effect of impaired renal or hepatic function on the pharmacokinetics of omalizumab. While no particular dose adjustment is recommended, omalizumab should be administered with caution in these patients.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed4374    
    Printed18    
    Emailed2    
    PDF Downloaded792    
    Comments [Add]    
    Cited by others 1    

Recommend this journal